MedKoo product information:

 Nandrolone Decanoate

nandrolone decanoate is the decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Nandrolone (19-nortestosterone) is an anabolic steroid that may be present naturally in the human body, albeit in minute quantities of less than 0.4 ng/ml.[citation needed] Nandrolone is most commonly sold commercially as its decanoate ester (Deca-Durabolin) and less commonly as a phenylpropionate ester (Durabolin). Nandrolone decanoate is used in the treatment of osteoporosis in postmenopausal women (though now not recommended) at a dose of 50 mg every three weeks. It is also used for some aplastic anaemias. The positive effects of the drug include muscle growth, appetite stimulation and increased red blood cell production and bone density. Clinical studies have shown it to be effective in treating anaemia, osteoporosis and some forms of neoplasia including breast cancer, and also acts as a progestin-based contraceptive. For these reasons, in the United States nandrolone received FDA approval in 1983. Because nandrolone is not broken down into DHT, the deleterious effects common to most anabolic steroids on the scalp, skin, and prostate are lessened to a degree; but is rather broken down to the much weaker androgen dihydronandrolone. The lack of alkylation on the 17α-carbon drastically reduces the drug's liver toxicity. Estrogenic effects resulting from reaction with aromatase are also mitigated as a result of the drug being a progestin, but effects such as gynaecomastia and reduced libido still occur in larger doses. Other side-effects can include erectile dysfunction and cardiovascular damage, as well as several ailments resulting from the drug's effect of lowering levels of luteinizing hormone through negative feedback. Erectile dysfunction is attributed to the weaker action of dihydronandrolone in the penis since dihydrotestosterone is a known sexual modulator.

(the above information was directly from http://en.wikipedia.org/wiki/Nandrolone_phenpropionate).

 1: Chawla B, Iqbal FM, Chawla MS. Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series. Compr Ther. 2009 Fall-Winter;35(3-4):199-203. PubMed PMID: 20043618.

2: Bidosee M, Karry R, Weiss-Messer E, Barkey RJ. Regulation of growth hormone receptors in human prostate cancer cell lines. Mol Cell Endocrinol. 2009 Oct 15;309(1-2):82-92. Epub 2009 Jun 18. PubMed PMID: 19540305.

3: Vougiouklakis T, Mitselou A, Batistatou A, Boumba V, Charalabopoulos K. First case of fatal pulmonary peliosis without any other organ involvement in a young testosterone abusing male. Forensic Sci Int. 2009 Apr 15;186(1-3):e13-6. Epub 2009 Feb 25. PubMed PMID: 19243902.

4: Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate. 2008 Oct 1;68(14):1570-81. PubMed PMID: 18668523.

5: Guarino G, Spampinato S. Nandrolone decreases mu opioid receptor expression in SH-SY5Y human neuroblastoma cells. Neuroreport. 2008 Jul 16;19(11):1131-5. PubMed PMID: 18596614.

6: Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):214-22. PubMed PMID: 18555683; PubMed Central PMCID: PMC2575079.

7: Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):236-43. Epub 2008 Apr 20. PubMed PMID: 18515094.

8: Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER. Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med. 2008 Jun;49(6):978-86. Epub 2008 May 15. PubMed PMID: 18483091; PubMed Central PMCID: PMC2435083.

9: Munson L. Contraception in felids. Theriogenology. 2006 Jul 1;66(1):126-34. Epub 2006 Apr 19. Review. PubMed PMID: 16626799.

10: Xin DQ, Zhu XH, Lai YQ, You R, Na YQ, Guo YL, Mao ZB. [Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer]. Beijing Da Xue Xue Bao. 2005 Dec 18;37(6):638-40. Chinese. PubMed PMID: 16378119.

11: Tokar EJ, Ancrile BB, Cunha GR, Webber MM. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation. 2005 Dec;73(9-10):463-73. PubMed PMID: 16351690.

12: Lasco A, Morini E, Maglitto D, Campennì A, Benvenga S. Disappearance of a virilizing adrenal tumor following therapy with cyproterone acetate. Endocr Relat Cancer. 2005 Dec;12(4):939-44. PubMed PMID: 16322333.

13: Chung BH, Lee HY, Lee JS, Young CY. Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett. 2006 May 18;236(2):222-8. Epub 2005 Jul 18. PubMed PMID: 16029925.

14: Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR, Boada LD. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005 May;39(5):e27. Review. PubMed PMID: 15849280; PubMed Central PMCID: PMC1725213.

15: Hartel A, Didier A, Ulbrich SE, Wierer M, Meyer HH. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes. J Steroid Biochem Mol Biol. 2004 Oct;92(3):187-97. PubMed PMID: 15555912.

16: Muddana SS, Price AM, MacBride MM, Peterson BR. 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor. J Med Chem. 2004 Oct 7;47(21):4985-8. PubMed PMID: 15456242.

17: Mueck AO, Seeger H, Wallwiener D. Endogenous estradiol metabolism during treatment with oral contraceptives. Int J Clin Pharmacol Ther. 2004 Mar;42(3):160-4. PubMed PMID: 15049436.

18: Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res. 2003 Aug 1;63(15):4698-704. PubMed PMID: 12907652.

19: Conner P, Söderqvist G, Skoog L, Gräser T, Walter F, Tani E, Carlström K, von Schoultz B. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat. 2003 Mar;78(2):159-65. PubMed PMID: 12725416.

20: Mueck AO, Seeger H, Wallwiener D. Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas. 2002 Oct 25;43(2):87-93. PubMed PMID: 12385856.

21: Lu L, Schulz H, Wolf DA. The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. BMC Cell Biol. 2002 Aug 20;3:22. Epub 2002 Aug 20. PubMed PMID: 12188931; PubMed Central PMCID: PMC122093.

22: Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol. 2002 Sep;85(1):151-9. Review. PubMed PMID: 12163220.

23: Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer. 2002 Mar 18;86(6):879-85. PubMed PMID: 11953818; PubMed Central PMCID: PMC2364138.

24: Mueck AO, Seeger H, Gräser T, Oettel M, Lippert TH. The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism. Horm Metab Res. 2001 Dec;33(12):744-7. PubMed PMID: 11753761.

25: Rimler A, Culig Z, Levy-Rimler G, Lupowitz Z, Klocker H, Matzkin H, Bartsch G, Zisapel N. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. Prostate. 2001 Oct 1;49(2):145-54. PubMed PMID: 11582594.

26: Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis. 2001 Sep;22(9):1399-403. PubMed PMID: 11532861.

27: Skouby SO. The rationale for a wider range of progestogens. Climacteric. 2000 Dec;3 Suppl 2:14-20. Review. PubMed PMID: 11379382.

28: Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate. 2001 Apr;47(1):1-13. PubMed PMID: 11304724.

29: Mitchell SH, Murtha PE, Zhang S, Zhu W, Young CY. An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol. 2000 Oct 25;168(1-2):89-99. PubMed PMID: 11064155.

30: Collett GP, Betts AM, Johnson MI, Pulimood AB, Cook S, Neal DE, Robson CN. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res. 2000 Aug;6(8):3241-8. PubMed PMID: 10955810.

31: Kumar A, Mikolajczyk SD, Hill TM, Millar LS, Saedi MS. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate. 2000 Aug 1;44(3):248-54. PubMed PMID: 10906742.

32: Desport JC, Blanc-Vincent MP, Gory-Delabaere G, Bachmann P, Béal J, Benamouzig R, Colomb V, Kere D, Melchior JC, Nitenberg G, Raynard B, Scheiner S, Senesse P. [Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)]. Bull Cancer. 2000 Apr;87(4):315-28. French. Erratum in: Bull Cancer 2000 Jun;87(6):490. PubMed PMID: 10827350.

33: Darnton SJ, Zgainski B, Grenier I, Allister K, Hiller L, McManus KG, Steyn RS. The use of an anabolic steroid (nandrolone decanoate) to improve nutritional status after esophageal resection for carcinoma. Dis Esophagus. 1999;12(4):283-8. PubMed PMID: 10770363.

34: Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol. 1999 Dec 10;386(1):33-40. PubMed PMID: 10611461.

35: Rosenberg Zand RS, Jenkins DJ, Diamandis EP. Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2. J Clin Lab Anal. 1999;13(5):241-5. PubMed PMID: 10494134.

36: Mukherjee A, Kirkovsky LI, Kimura Y, Marvel MM, Miller DD, Dalton JT. Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol. 1999 Oct 15;58(8):1259-67. PubMed PMID: 10487527.

37: Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999 May 1;59(9):2136-41. PubMed PMID: 10232600.

38: Rijks LJ, van den Bos JC, van Doremalen PA, Boer GJ, de Bruin K, Janssen AG, van Royen EA. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization. Nucl Med Biol. 1998 Nov;25(8):791-8. PubMed PMID: 9863568.

39: van den Bos JC, Rijks LJ, van Doremalen PA, de Bruin K, Janssen AG, van Royen EA. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 1: Synthesis and in vitro pharmacological characterization. Nucl Med Biol. 1998 Nov;25(8):781-9. PubMed PMID: 9863567.

40: Tang W, Schneider MR, Eisenbrand G. Novel steroid-linked conjugates of 17 beta-[N-[N'-(2-chloroethyl)-N'-nitroso]carbamoyl]amino acids and their antineoplastic activity against Noble Nb prostate carcinoma model in rats. Anticancer Drug Des. 1998 Oct;13(7):815-24. PubMed PMID: 9807164.

41: Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol. 1998 Apr;25(2 Suppl 6):104-11. Review. PubMed PMID: 9625392.

42: Prescott JL, Tindall DJ. Clathrin gene expression is androgen regulated in the prostate. Endocrinology. 1998 Apr;139(4):2111-9. PubMed PMID: 9529000.

43: Radis CD, Callis KP. Systemic lupus erythematosus with membranous glomerulonephritis and transverse myelitis associated with anabolic steroid use. Arthritis Rheum. 1997 Oct;40(10):1899-902. PubMed PMID: 9336429.

44: Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol. 1997 Jun;24(3):277-87. Review. PubMed PMID: 9208884.

45: Markiewicz L, Gurpide E. Estrogenic and progestagenic activities of physiologic and synthetic androgens, as measured by in vitro bioassays. Methods Find Exp Clin Pharmacol. 1997 May;19(4):215-22. PubMed PMID: 9228646.

46: Betts AM, Waite I, Neal DE, Robson CN. Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. FEBS Lett. 1997 Apr 1;405(3):328-32. PubMed PMID: 9108313.

47: Szelei J, Jimenez J, Soto AM, Luizzi MF, Sonnenschein C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology. 1997 Apr;138(4):1406-12. PubMed PMID: 9075695.

48: Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 1997 Mar 15;57(6):1086-90. PubMed PMID: 9067276.

49: Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer. 1997 Jan 1;79(1):169-76. PubMed PMID: 8988742.

50: Anabolic steroid boosts weight. GMHC Treat Issues. 1996 Sep;10(9):8-9. PubMed PMID: 11363845.

51: Vansteenkiste JF, Simons JP, Wouters EF, Demedts MG. Hormonal treatment in advanced non-small cell lung cancer: fact or fiction? Eur Respir J. 1996 Aug;9(8):1707-12. Review. PubMed PMID: 8866599.

52: Bonasera TA, O'Neil JP, Xu M, Dobkin JA, Cutler PD, Lich LL, Choe YS, Katzenellenbogen JA, Welch MJ. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med. 1996 Jun;37(6):1009-15. PubMed PMID: 8683293.

53: Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):439-44. PubMed PMID: 8541241.

54: Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol. 1995 Dec;55(3-4):423-37. PubMed PMID: 8541240.

55: Botella J, Duranti E, Viader V, Duc I, Delansorne R, Paris J. Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells. J Steroid Biochem Mol Biol. 1995 Oct;55(1):77-84. PubMed PMID: 7577723.

56: Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995 May;52(5):459-67. PubMed PMID: 7748811.

57: Lydén E, Cvetkovska E, Westin T, Oldfors A, Soussi B, Gustafsson B, Edström S. Effects of nandrolone propionate on experimental tumor growth and cancer cachexia. Metabolism. 1995 Apr;44(4):445-51. PubMed PMID: 7723666.

58: Swinnen JV, Esquenet M, Heyns W, Rombauts W, Verhoeven G. Androgen regulation of the messenger RNA encoding diazepam-binding inhibitor/acyl-CoA-binding protein in the human prostatic adenocarcinoma cell line LNCaP. Mol Cell Endocrinol. 1994 Sep;104(2):153-62. PubMed PMID: 7527352.

59: Traish AM, Netsuwan N. 7 alpha-17 alpha-Dimethyl-19-nortestosterone (mibolerone) induces conformational changes in progesterone receptors distinct from those induced by ORG 2058. Steroids. 1994 Jun;59(6):362-70. PubMed PMID: 7940614.

60: Audran M. [Iatrogenic demineralizing osteopathies]. Presse Med. 1994 Feb 12;23(6):271-3. Review. French. PubMed PMID: 8208675.

61: Hall RE, Birrell SN, Tilley WD, Sutherland RL. MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer. 1994;30A(4):484-90. PubMed PMID: 8018407.

62: Wolf DA, Herzinger T, Hermeking H, Blaschke D, Hörz W. Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol. 1993 Jul;7(7):924-36. PubMed PMID: 8413317.

63: Murtha P, Tindall DJ, Young CY. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry. 1993 Jun 29;32(25):6459-64. PubMed PMID: 7686046.

64: Sundaram K, Kumar N, Bardin CW. 7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception. Ann Med. 1993 Apr;25(2):199-205. Review. PubMed PMID: 8489761.

65: Hoyte RM, Brown TJ, MacLusky NJ, Hochberg RB. 7 alpha-Methyl-17 alpha-(E-2'-[125I]iodovinyl)-19-nortestosterone: a new radioligand for the detection of androgen receptor. Steroids. 1993 Jan;58(1):13-23. PubMed PMID: 8430441.

66: Khankhanian NK, Hammers YA, Kowalski P. Exuberant local tissue reaction to intramuscular injection of nandrolone decanoate (Deca-Durabolin)--a steroid compound in a sesame seed oil base--mimicking soft tissue malignant tumors: a case report and review of the literature. Mil Med. 1992 Dec;157(12):670-4. Review. PubMed PMID: 1470383.

67: Pan J, Hong JY, Yang CS. Post-transcriptional regulation of mouse renal cytochrome P450 2E1 by testosterone. Arch Biochem Biophys. 1992 Nov 15;299(1):110-5. PubMed PMID: 1444443.

68: Liu A, Carlson KE, Katzenellenbogen JA. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem. 1992 May 29;35(11):2113-29. PubMed PMID: 1597861.

69: Wolf DA, Schulz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol. 1992 May;6(5):753-62. PubMed PMID: 1376410.

70: Andrews PE, Young CY, Montgomery BT, Tindall DJ. Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. Cancer Res. 1992 Mar 15;52(6):1525-9. PubMed PMID: 1371717.

71: MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer. 1992 Feb;65(2):177-82. PubMed PMID: 1739613; PubMed Central PMCID: PMC1977738.

72: Castagnetta L, Carruba G, Fecarotta E, Lo Casto M, Cusimano R, Pavone-Macaluso M. Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate. Urol Res. 1992;20(2):127-32. PubMed PMID: 1372770.

73: Steinsapir J, Socci R, Reinach P. Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun. 1991 Aug 30;179(1):90-6. PubMed PMID: 1883394.

74: Krongrad A, Wilson CM, Wilson JD, Allman DR, McPhaul MJ. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol Cell Endocrinol. 1991 Apr;76(1-3):79-88. PubMed PMID: 1820979.

75: Salman M, Chamness GC. A potential radioiodinated ligand for androgen receptor: 7 alpha-methyl-17 alpha-(2'-(E)-iodovinyl)-19-nortestosterone. J Med Chem. 1991 Mar;34(3):1019-24. PubMed PMID: 2002446.

76: Gontsa AA, Moldovan VI, Simbirtseva LP. [Preventive treatment of local radiation injuries in combined radiotherapy of rectal cancer]. Med Radiol (Mosk). 1991;36(2):17-20. Russian. PubMed PMID: 1996065.

77: Seliger E, Kaltwasser P, Schneider F, Rothe K, Buchmann J. [Steroid receptors in the gestagen treatment of endometriosis]. Ther Umsch. 1990 Dec;47(12):945-50. German. PubMed PMID: 2096479.

78: Suzuki T, Horibe I, Uchida N, Ezumi K, Uchida K, Takeda K, Tanaka A, Nishizawa Y, Matsumoto K. Effects of antiandrogens on growth of androgen-dependent mouse mammary tumor (Shionogi carcinoma 115) in vivo and in vitro. J Steroid Biochem Mol Biol. 1990 Nov 30;37(4):559-67. PubMed PMID: 2278840.

79: Pain JA, Wickremesinghe SS, Bradbeer JW. Combined tamoxifen and anabolic steroid as primary treatment for breast carcinoma in the elderly. Eur J Surg Oncol. 1990 Jun;16(3):225-8. PubMed PMID: 2347416.

80: Olea N, Sakabe K, Soto AM, Sonnenschein C. The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology. 1990 Mar;126(3):1457-63. PubMed PMID: 2307113.

81: Kirkali Z, Cowan S, Leake RE. Androgen receptors in transitional cell carcinoma. Int Urol Nephrol. 1990;22(3):231-4. PubMed PMID: 2210977.

82: Saltanov AI, Ordukhanian ZS, Kolomiĭskiĭ AIu, Drachinskiĭ KN, Tseĭtlin GIa, Gorozhanskaia EG, Gromova NV, Smirnova KD, Mendzheritskiĭ IuM. [Surgical stress in pediatric oncology]. Vopr Onkol. 1990;36(11):1326-30. Russian. PubMed PMID: 2177935.

83: Schulz P, Wolf D, Arbusow V, Bojar H, Klobeck HG, Fittler F. The synthetic androgen mibolerone induces transient suppression of the transformed phenotype in an androgen responsive human prostatic carcinoma cell line. Andrologia. 1990;22 Suppl 1:56-66. PubMed PMID: 2151880.

84: Kemp CJ, Drinkwater NR. Genetic variation in liver tumor susceptibility, plasma testosterone levels, and androgen receptor binding in six inbred strains of mice. Cancer Res. 1989 Sep 15;49(18):5044-7. PubMed PMID: 2766275.

85: Salman M, Stotter PL, Chamness GC. 125I-ligand for progesterone receptor: 17 alpha-(6'-iodohex-1'-ynyl)-19-nortestosterone. J Steroid Biochem. 1989 Jul;33(1):25-31. PubMed PMID: 2761264.

86: Köhler G, Lembke S, Brachmann K, Foth D, Happke S. [Behavior of parameters of liver metabolism in intermediate-term use of the gestagen dienogest in the treatment of endometriosis]. Zentralbl Gynakol. 1989;111(12):807-10. German. PubMed PMID: 2763750.

87: Ginsburg KA, Moghissi KS. Alternate delivery systems for contraceptive progestogens. Fertil Steril. 1988 May;49(5 Suppl 2):16S-30S. Review. PubMed PMID: 3282932.

88: Perel E, Daniilescu D, Kharlip L, Blackstein M, Killinger DW. Steroid modulation of aromatase activity in human cultured breast carcinoma cells. J Steroid Biochem. 1988 Apr;29(4):393-9. PubMed PMID: 3374128.

89: Traish AM, Williams DF, Hoffman ND, Wotiz HH. Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates. Prog Clin Biol Res. 1988;262:145-60. PubMed PMID: 3375279.

90: Brandes SJ, Katzenellenbogen JA. Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate. Int J Rad Appl Instrum B. 1988;15(1):53-67. Review. PubMed PMID: 3280523.

91: Kellokumpu-Lehtinen P, Huovinen R, Johansson R. Hormonal treatment of advanced breast cancer. A randomized trial of tamoxifen versus nandrolone decanoate. Cancer. 1987 Nov 15;60(10):2376-81. PubMed PMID: 3664426.

92: Salman M, Ruiz AA, Stotter PL, Chamness GC. A progesterone receptor affinity chromatography reagent: 17 alpha-hexynyl nortestosterone sepharose. J Steroid Biochem. 1987 Mar;26(3):383-91. PubMed PMID: 3586653.

93: Grill HJ, Heubner A, Pollow K, Manz B, Schulze PE, Hofmeister H, Laurent H, Wiechert R, Elger W. (Z)-17 beta-hydroxy-17 alpha-(2-[125I]iodovinyl)-4-estren-3-one: a new specific gamma-emitting ligand for determination of progesterone receptor. J Clin Chem Clin Biochem. 1987 Feb;25(2):107-12. PubMed PMID: 3572309.

94: Köhler G, Göretzlehner G, Amon I. [Therapy of endometriosis with dienogest]. Zentralbl Gynakol. 1987;109(12):795-801. German. PubMed PMID: 3630463.

95: Liu GS, Li GC. Further study of five-drug combined chemotherapy for advanced breast cancer. Chin Med J (Engl). 1986 Sep;99(9):757-9. PubMed PMID: 3100238.

96: de Sanctis C, De Luca S, Succi A, Gargiulo P, Mugnaini L, Antilli A, Signora M, Cruciani AR. [Hematological toxicity and nandrolone decanoate during polychemotherapy of bronchogenic carcinoma. Preliminary note]. Clin Ter. 1986 Aug 15;118(3):183-6. Italian. PubMed PMID: 3757462.

97: Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponce AT, Heber D, Block JB. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer. 1986 Jul 1;58(1):183-6. PubMed PMID: 3518910.

98: Tseng L, Tseng JK, Mann WJ, Chumas JC, Stone ML, Mazella J, Sun B, Amalfitano TG, Wallach RC. Endocrine aspects of human uterine sarcoma: a preliminary study. Am J Obstet Gynecol. 1986 Jul;155(1):95-101. PubMed PMID: 2942037.

99: Erny R, Isnard S, Boubli L. [Progestogen tests after the menopause]. Rev Fr Gynecol Obstet. 1986 Apr;81(4):195-8. French. PubMed PMID: 3715302.

100: Lesna M, Taylor W. Liver lesions in BALB/C mice induced by an anabolic androgen (Decadurabolin), with and without pretreatment with diethylnitrosamine. J Steroid Biochem. 1986 Jan;24(1):449-53. PubMed PMID: 3702427.

101: Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer. 1985 Oct 1;56(7):1696-700. PubMed PMID: 4027900.

102: Zurborn KH, Sondermann I, Gross WL. [Decrease of paraprotein secretion despite progressive tumor cell proliferation by cytostatic drug therapy of plasmacytoma]. Internist (Berl). 1985 Sep;26(9):584-6. German. PubMed PMID: 3905684.

103: Seaman WJ. Canine ovarian fibroma associated with prolonged exposure to mibolerone. Toxicol Pathol. 1985;13(3):177-80. PubMed PMID: 4070927.

104: Heinonen E, Alanko A, Gröhn P, Rissanen P. Nandrolone decanoate added to tamoxifen in the treatment of advanced breast cancer. Breast Cancer Res Treat. 1985;5(1):75-80. PubMed PMID: 3978249.

105: Chlebowski RT. Critical evaluation of the role of nutritional support with chemotherapy. Cancer. 1985 Jan 1;55(1 Suppl):268-72. Review. PubMed PMID: 3917360.

106: Turner R. Deca-Durabolin and cytotoxic drugs. Acta Endocrinol Suppl (Copenh). 1985;271:70-9. PubMed PMID: 3878056.

107: Yamagishi H, Kobayashi M, Konosu H, Kurioka H, Naito K, Sonoyama T, Nishimoto T, Hashimoto I. [Effect of anabolic steroid on immune response]. Gan To Kagaku Ryoho. 1984 Mar;11(3):420-6. Japanese. PubMed PMID: 6367663.

108: Carrasco D, Pallardo L, Prieto M, Moll JL, Cruz JM, Berenguer J. Hepatic adenomata and androgen treatment. Ann Intern Med. 1984 Feb;100(2):316. PubMed PMID: 6691682.

109: Iino Y, Yamazaki K, Ogawa T, Hirai T, Arai T, Ishikawa H, Endo K, Kawai T, Izuo M, Takikawa H. [Effect of medroxyprogesterone acetate (MAP) and vitamin C on DMBA induced rat mammary cancer in relation to estrogen receptor(ER)]. Gan No Rinsho. 1983 Aug;29(9):949-54. Japanese. PubMed PMID: 6225884.

110: Turani H, Levi J, Zevin D, Kessler E. Hepatic lesions in patients on anabolic androgenic therapy. Isr J Med Sci. 1983 Apr;19(4):332-7. PubMed PMID: 6853130.

111: Schwartz ML, Israel HL. Severe anemia as a manifestation of metastatic jugular paraganglioma. Arch Otolaryngol. 1983 Apr;109(4):269-72. PubMed PMID: 6299257.

112: Gunnarsson PO, Ellman M, Fabiansson E, Gunnarsson K, Jensen G, Müntzing J. Antitumour activity, toxicity and disposition of LS 1727, a nitroso-chloroethyl carbamate of 19-nortestosterone, in rats and mice. Acta Pharmacol Toxicol (Copenh). 1981 Oct;49(4):290-7. PubMed PMID: 7342689.

113: Bibby MC, Double JA, Mughal MA. Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours. Br J Cancer. 1981 Oct;44(4):572-7. PubMed PMID: 7295514; PubMed Central PMCID: PMC2010805.

114: Sasson S, Mayer M. Resistance to androgen in murine lymphosarcoma lines resistant or sensitive to glucocorticoid hormone. Br J Cancer. 1981 Jul;44(1):127-8. PubMed PMID: 6894859; PubMed Central PMCID: PMC2010650.

115: Yoshida S, Sanui H, Ohhara R, Nomoto K, Takeya K. Restorative effects of nandrolone decanoate on the mononuclear phagocyte system in tumor-bearing mice. Gann. 1981 Jun;72(3):435-9. PubMed PMID: 7319199.

116: Müntzing J, Kirdani RY, Williams PD, Murphy GP. Effect of LS 1727, a nitrosocarbamate of 19-nortestosterone, on the R-3327 rat prostatic adenocarcinoma. Res Commun Chem Pathol Pharmacol. 1981 May;32(2):309-16. PubMed PMID: 7244365.

117: Hartley-Asp B, Wilkinson R, Venitt S, Harrap KR. Studies on the mechanism of action of LS 1727, a nitrosocarbamate of 19-nortestosterone. Acta Pharmacol Toxicol (Copenh). 1981 Feb;48(2):129-38. PubMed PMID: 6167141.

118: Zbytniewski Z, Kanclerz A, Boeryd B. Influence of aspirin and/or anabolic steroid (nandrolone decanoate) on experimental metastasis formation. Arch Immunol Ther Exp (Warsz). 1981;29(6):697-701. PubMed PMID: 7349091.

119: Peek U, Tanneberger S, Heise E, Görlich M, Nissen E, Marx G, Projan A, Winkler R, Kunde D, Bodek B. High risk breast cancer: long-term surgical adjuvant therapy based on predictive tests - preliminary report. Arch Geschwulstforsch. 1981;51(1):139-51. PubMed PMID: 7259436.

120: Spiers AS, DeVita SF, Allar MJ, Richards S, Sedransk N. Beneficial effects of an anabolic steroid during cytotoxic chemotherapy for metastatic cancer. J Med. 1981;12(6):433-45. PubMed PMID: 7033426.

121: Kopera H. [Do anabolic steroids protect bone marrow during cytostatic therapy?]. Med Klin. 1980 Jul 18;75(15):539-43. Review. German. PubMed PMID: 7001201.

122: Ow KT, Sarfaty GA, Nash AR. The effects of steroids on phytohaemagglutin-induced lymphoblastogenesis. J Steroid Biochem. 1980 Jan;12:303-7. PubMed PMID: 7421218.

123: Tsyplenkov VG. [State of the biliary system in children with Hodgkin's disease]. Pediatriia. 1980;(5):52-3. Russian. PubMed PMID: 7393682.

124: Bhan AK, Kumar V, Bennett M. Differential growth of allogeneic bone marrow and leukemia cells in irradiated guinea pigs. J Immunol. 1979 Nov;123(5):1952-9. PubMed PMID: 385774.

125: Marcuello Gaspar E, Germa Lluch JR, Abad Esteve A, Badia Canto A. [Experience with weekly intravenous 5-fluorouracil in advanced colonic and rectal neoplasms]. Rev Esp Enferm Apar Dig. 1979 Apr;55(4):365-76. Spanish. PubMed PMID: 493637.

126: Bouveng R, Ellman M, Gunnarsson PO, Jensen G, Liljekvist J, Müntzing J. Effects of LS 1727, a nitrosocarbamate of 19-nortestosterone, on dimethylbenz (a)anthracene-induced mammary tumors in the rat. Eur J Cancer. 1979 Apr;15(4):407-14. PubMed PMID: 108107.

127: Holtzhausen GH. [Clinical aspects of the anti-androgens]. S Afr Med J. 1979 Mar 24;55(13):516-21. Review. Afrikaans. PubMed PMID: 156405.

128: Wolff G, Rieche K. [Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone-testololactone-drostanolone]. Onkologie. 1978 Aug;1(4):172-4. German. PubMed PMID: 362297.

129: Algeri R, Camarri E, Giomi S. [High doses of anabolic steroids in collateral therapy of malignant neoplasms. Results with 19-norandrostenolone undecylate]. Clin Ter. 1978 Jun 15;85(5):505-15. Italian. PubMed PMID: 679635.

130: Trams G. [Basis of gestagen therapy of endometrial carcinoma]. Dtsch Med Wochenschr. 1978 Mar 31;103(13):574-7. German. PubMed PMID: 639688.

131: Gekht BM, Kuralesin MG, Gnezditskaia EV, Shagal DI. [Effect of hormonal therapy on the level of antibiodies to antigens of thymus epithelial tissue in myasthenia]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1978;78(8):1129-34. Russian. PubMed PMID: 358705.

132: Romero CH, Claflin W, Frank F, Chang TS, Purchase HG. Vaccination immunity to selected diseases in chickens fed the androgen analog mibolerone. Poult Sci. 1978 Jan;57(1):74-9. PubMed PMID: 209430.

133: Broxmeyer HE, Ralph P. In vitro regulation of a mouse myelomonocytic leukemia line adapted to culture. Cancer Res. 1977 Oct;37(10):3578-84. PubMed PMID: 302736.

134: Romero CH, Frank FR. Immune responses and prevention of lymphoid leukosis tumors in chickens fed an androgen analog. Adv Exp Med Biol. 1977;88:355-62. PubMed PMID: 200124.

135: Edelstyn GA, MacRae KD. Concomitant androgen therapy in the management of advanced breast cancer by cyclical combined chemotherapy. Clin Oncol. 1976 Dec;2(4):403-5. PubMed PMID: 1024767.

136: Nilsson A, Broomé-Karlsson A. Influence of steroid hormones on the carcinogenicity of 90Sr. Acta Radiol Ther Phys Biol. 1976 Oct;15(5):417-26. PubMed PMID: 1070217.

137: Chowdhury MS, Banks AJ, Bond WH, Jones WG, Ward HW. A comparison of drostanolone propionate (Masteril) and nandrolone decanoate (Deca-durabolin) in the treatment of breast carcinoma. Clin Oncol. 1976 Sep;2(3):203-6. PubMed PMID: 1036981.

138: Liao S, Hung SC, Tymoczko JL, Liang T. Active forms and biodynamics of the androgen-receptor in various target tissues. Curr Top Mol Endocrinol. 1976;4:139-51. Review. PubMed PMID: 800356.

139: van Nie R, Hilgers J. Genetic analysis of mammary tumor induction and expression of mammary tumor virus antigen in hormone-treated ovariectomized GR mice. J Natl Cancer Inst. 1976 Jan;56(1):27-32. PubMed PMID: 176379.

140: Bennett MB, Helman P, Palmer P. Hormonal therapy of breast cancer with special reference to Masteril therapy. S Afr Med J. 1975 Nov 15;49(49):2036-40. PubMed PMID: 1242823.

141: Snigurowicz J, Rostkowska J, Slomkowski M, Sielczak M, Kraj M, Krzemińska-Lawkowiczowa I. [12 years of Melphalan therapy in a case of Igu-lambda plasmacytoma and resulting therapeutic suggestions]. Pol Arch Med Wewn. 1975 Oct;54(4):369-77. Polish. PubMed PMID: 810778.

142: Dickey RP, Stone SC. Drugs that affect the breast and lactation. Clin Obstet Gynecol. 1975 Jun;18(2):95-111. Review. PubMed PMID: 1095275.

143: Hadziev S, Kavaklieva-Dimtrova J, Mandulova P. Therapeutic effect of a water-salt extract from BCG in two patients with advanced breast cancer. Neoplasma. 1975;22(3):269-72. PubMed PMID: 1099468.

144: Burn JI, Cooke WM. Effect of nandrolone phenylpropionate (NSC-23162e) on the bone marrow suppression caused by cyclophosphamide (NSC-26271): a clinical trial. Cancer Chemother Rep. 1974 Nov-Dec;58(6):867-70. PubMed PMID: 4615786.

145: McBride WG, Macmillan IS, Heber KR. A comparative study of adverse effects of oral contraceptives. Med J Aust. 1974 Aug 17;2(7):246-50. PubMed PMID: 4422181.

146: Artico M. [Chemotherapy of tumors. 3. Chemical review of natural antineoplastic agents: antibiotics and related compounds; enzymes and hormones]. Farmaco Sci. 1974 Aug;29(8):598-646. Review. Italian. PubMed PMID: 4136312.

147: Hähnel R, Twaddle E. The steroid specificity of the estrogen-receptor of human breast carcinoma. J Steroid Biochem. 1974 Apr;5(2):119-22. PubMed PMID: 4366805.

148: Besa EC, Gorshein D, Gardner FH. Androgens and human blood volume changes. Comparison in normal and various anemic states. Arch Intern Med. 1974 Mar;133(3):418-25. PubMed PMID: 4521323.

149: Evens RP, Amerson AB. Androgens and erythropoiesis. J Clin Pharmacol. 1974 Feb-Mar;14(2):94-101. PubMed PMID: 4405947.

150: Kahn SB, Conroy JF, Brodsky I. Effect of nandrolone phenpropionate on myelopoiesis. J Med. 1974;5(6):303-9. PubMed PMID: 4528544.

151: Talley RW, Haines CR, Waters MN, Goldenberg IS, Olson KB, Bisel HF. A dose-response evaluation of androgens in the treatment of metastatic breast cancer. Cancer. 1973 Aug;32(2):315-20. PubMed PMID: 4579091.

152: Haugen OA. Distribution of pituitary cell types in relation to the histology of the prostate in elderly men. An analysis in an autopsy series. Acta Pathol Microbiol Scand A. 1973 Jul;81(4):411-24. PubMed PMID: 4130924.

153: Pentycross CR, Toussis D, McKinna JA, Lawler SD, Greening WP. Effect of hormone therapy on mitogenic responses of lymphocytes from patients with cancer of the breast. Lancet. 1973 Jul;2(7822):177-9. PubMed PMID: 4124253.

154: Engelsman E, Persijn JP, Korsten CB, Cleton FJ. Oestrogen receptor in human breast cancer tissue and response to endocrine therapy. Br Med J. 1973 Jun 30;2(5869):750-2. PubMed PMID: 4352316; PubMed Central PMCID: PMC1589773.

155: Cole MP, Todd ID, Wilkinson PM. Cyclophosphamide and nandrolone decanoate in the treatment of advanced carcinoma of the breast--results of a comparative controlled trial of the agents used singly and in combination. Br J Cancer. 1973 May;27(5):396-9. PubMed PMID: 4576562; PubMed Central PMCID: PMC2008797.

156: Engelsman E, Korsten CB, Persijn JP, Cleton FJ. Human breast cancer and estrogen receptor. Arch Chir Neerl. 1973;25(4):393-7. PubMed PMID: 4771976.

157: Wolff G, Prahl B. [A controlled clinical trial for hormonal and combined cyclophosphamide-hormonal treatment of incurable breast cancer (author's transl)]. Arch Geschwulstforsch. 1973;41(4):363-72. German. PubMed PMID: 4747050.

158: Brodsky I. The role of androgens and anabolic steroids in the treatment of cancer. Semin Drug Treat. 1973 Summer;3(1):15-25. PubMed PMID: 4740371.

159: Rawbone RG, Bagshawe KD. Anabolic steroids and bone marrow toxicity during therapy with methotrexate. Br J Cancer. 1972 Oct;26(5):395-401. PubMed PMID: 4343678; PubMed Central PMCID: PMC2008626.

160: Helman P, Bennett MB. Hormone therapy of breast cancer with special reference to masteril therapy. S Afr Med J. 1972 Aug 26;46(34):1195-9. PubMed PMID: 5068714.

161: Evans JT, Elias EG. The erythropoietic response to anabolic therapy in patients receiving radiotherapy. J Clin Pharmacol New Drugs. 1972 Feb-Mar;12(2):101-4. PubMed PMID: 4550604.

162: Mannes P, Derriks R, Moens R. [Long-term survival after treatment of breast cancer thoracic metastases through the association, right from the beginning, of hormonotherapy and non hormonal antineoplastic chemotherapy (author's transl)]. Acta Tuberc Pneumol Belg. 1971 Sep-Dec;62(5):473-77. French. PubMed PMID: 5172849.

163: Najean Y, Dresh C, Laprevotte I. [Long-term treatment of medullary insufficiency with androgens]. Minerva Med. 1971 Jun 27;62(51):2588-97. Italian. PubMed PMID: 5566872.

164: Hormones in advanced cancer. Br Med J. 1971 Jun 26;2(5764):760-3. PubMed PMID: 4253671; PubMed Central PMCID: PMC1796325.

165: Cooke WM, Burn JI. The effect of nandrolone phenylpropionate (Durabolin) on the bone-marrow suppression caused by cyclophosphamide. Br J Surg. 1971 Apr;58(4):302-3. PubMed PMID: 4929363.

166: Saito S. [Effect of ecdysterone on various blood factors in the rat]. Horumon To Rinsho. 1971 Mar;19(3):228-32. Japanese. PubMed PMID: 5165065.

167: Petrow V. Antifertility agents. Prog Med Chem. 1971;8(2):171-229. Review. PubMed PMID: 4947236.

168: Nelson RM, Rakoff AE. Hirsutism and acne treated by an androgen antagonist. Obstet Gynecol. 1970 Nov;36(5):748-52. PubMed PMID: 4248736.

169: Loewe-Lyon S, Salat J. [Female pseudohermaphroditism of therapeutic origin. Apropos of a case]. Gynecol Obstet (Paris). 1970 Mar-Apr;69(2):161-86. French. PubMed PMID: 5446033.

170: Kanzler G, Firusian N, Wetter O. [Treatment of plasmacytoma using anabolic steroids]. Med Welt. 1970 Feb 21;8:304-7. German. PubMed PMID: 5444233.

171: Böttcher D, Maas D, Wendt F, Schubothe H. [Anemia caused by erythroblastopenia in adult age]. Klin Wochenschr. 1970 Jan 15;48(2):96-104. German. PubMed PMID: 5286483.

172: Zachmann M, Prader A. Anabolic and androgenic affect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol Metab. 1970 Jan;30(1):85-95. PubMed PMID: 4311616.

173: Kleibel F. [Long-acting anabolic agent (clinibolin) as an adjuvant in tumor therapy]. Munch Med Wochenschr. 1969 Nov 21;111(47):2452-4. German. PubMed PMID: 5395737.

174: Macmichael IM. Management of choroidal metastases from breast carcinoma. Br J Ophthalmol. 1969 Nov;53(11):782-5. PubMed PMID: 5358526; PubMed Central PMCID: PMC506757.

175: Stacher A, Stöckl W, Weiser M. [Changes in the amino acid pool in multiple myelomas]. Blut. 1969 May;19(2):73-8. German. PubMed PMID: 5783103.

176: Daiber A, Soerensen R, Melendez M. [Monoclonal hyperimmunoglobulinemia (plasmacytoma and primary macroglobulinemia): study of 10 cases]. Sangre (Barc). 1969;14(3):273-88. Spanish. PubMed PMID: 5001978.

177: Atkins H, Bulbrook RD, Falconer MA, Hayward JL, MacLean KS, Schurr PH. Ten years' experience of sterioid assays in the management of breast cancer. A review. Lancet. 1968 Dec 14;2(7581):1255-60. PubMed PMID: 4177467.

178: Dendy PP. Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents. J Obstet Gynaecol Br Commonw. 1968 Dec;75(12):1256-61. PubMed PMID: 4236256.

179: Demol R. [Hormone treatment of breast cancer in the advanced phase]. Brux Med. 1968 Oct;48(10):665-9. French. PubMed PMID: 5757971.

180: Ronzoni G, Alquati P, Pola P, Alcini E. [Study of prostatic carcinogenesis, using 20-methyl-cholanthrene in albino rats]. Chir Patol Sper. 1968 Oct;16(5):435-44. Italian. PubMed PMID: 4313478.

181: Dao TL, Libby PR. Conjugation of steroid hormones by normal and neoplastic tissues. J Clin Endocrinol Metab. 1968 Oct;28(10):1431-9. PubMed PMID: 4234586.

182: Arthur K. Some aspects of chemotherapy in breast carcinomatosis. Clin Radiol. 1968 Jul;19(3):351-6. PubMed PMID: 4175702.

183: Murata S. [Study on the metabolism of 17 alpha-ethynyl-19-nortestosterone and 17 alpha-ethynyl estrenol in vivo]. Nippon Naibunpi Gakkai Zasshi. 1968 Feb 20;43(11):1083-96. Japanese. PubMed PMID: 5690578.

184: Mannes P, Derriks R, Moens R, Heynen E. [Antineoplastic polychemotherapy in thoracic pathology]. Poumon Coeur. 1968;24(1):83-91. French. PubMed PMID: 4968018.

185: Keast D. Runting syndromes, autoimmunity, and neoplasia. Adv Cancer Res. 1968;11:43-71. Review. PubMed PMID: 4305561.

186: Arakawa K. [Clinical studies on the effect of anabolic steroids in the therapy of cervix cancer. 2. Effect on protein metabolism in radiotherapy]. Nippon Naibunpi Gakkai Zasshi. 1967 Nov 20;43(8):808-21. Japanese. PubMed PMID: 5626431.

187: Mohri T. Effects of cortisol and 19-nortestosterone on the free amino acid pools and amino acid uptake of cultured cells. Endocrinology. 1967 Sep;81(3):454-60. PubMed PMID: 6033185.

188: Stoll BA. Progestin therapy of breast cancer: comparison of agents. Br Med J. 1967 Aug 5;3(5561):338-41. PubMed PMID: 6029163; PubMed Central PMCID: PMC1841969.

189: Krasilnikoff PA. Myelofibrosis and myeloid leukaemia. Acta Paediatr Scand. 1967 Jul;56(4):424-9. PubMed PMID: 5232027.

190: Baluda MA. The role of the bursa-dependent lymphoid tissue in oncogenesis by avian myeloblastosis virus. Virology. 1967 Jul;32(3):428-37. PubMed PMID: 4291304.

191: Damsté PH. Voice change in adult women caused by virilizing agents. J Speech Hear Disord. 1967 May;32(2):126-32. PubMed PMID: 6024312.

192: Hortling H, Malmio K. [Treatment of metastasizing breast cancer with anabolic steroids]. Nord Med. 1967 Mar 2;77(9):275-9. Swedish. PubMed PMID: 6020758.

193: Redon H, Dupas M. [Apropos of intra-arterial chemotherapy in the treatment of breast cancers]. Mem Acad Chir (Paris). 1966 Dec 14;92(31):879-90. French. PubMed PMID: 5984514.

194: Biedermann C, Obolensky W, Scoglio P, Zürcher WO. [Anabolic treatment combined with an antimitotic agent in order to prevent leukocyte decrease]. Ther Umsch. 1966 Dec;23(12):509-15. French. PubMed PMID: 5980438.

195: Doorenbos H. [Conservative hormonal treatment of metastatic mammary cancer]. Neurochirurgie. 1966 Nov;12(6):703-4. French. PubMed PMID: 5972235.

196: Kleibel F. [Pathogenesis and treatment of radiogenic hypotensive circulation disorders]. Dtsch Med J. 1966 May 31;17(10):326-9. German. PubMed PMID: 4964563.

197: Ishihara S. [Experimental studies on the aromatization of synthetic progestins]. Nippon Naibunpi Gakkai Zasshi. 1966 Apr 20;42(1):55-68. Japanese. PubMed PMID: 6007485.

198: Wendt F, Doyen A, Schoop W, Schubothe H, Hunstein W, Fliedner TM, Wedler HW. [Erythroblastophthisis in thymoma. Report on 2 observations with remission]. Schweiz Med Wochenschr. 1965 Oct 30;95(44):1494-9. German. PubMed PMID: 5880242.

199: Bernardelli E, Osvaldo A. [Research on the pathogenesis of avian erythremia]. Schweiz Med Wochenschr. 1965 Oct 30;95(44):1487-90. French. PubMed PMID: 5219227.

200: Verne J, Roth PC. [Results of a new series of experiments on the prevention of experimental cancer]. Bull Assoc Fr Etud Cancer. 1965 Oct-Dec;52(4):359-62. French. PubMed PMID: 5881434.

201: VOLK H, WILDE RC, CARABASI RA, BISEL HF. ANTITUMOR EFFICACY OF NORANDROLONE PHENPROPIONATE COMPARED WITH TESTOSTERONE PROPIONATE IN ADVANCED BREAST CANCER. Cancer. 1965 May;18:651-5. PubMed PMID: 14278898.

202: SAARNE A, BJERSTAF L, EKMAN B. STUDIES ON THE NITROGEN BALANCE IN THE HUMAN DURING LONG-TERM TREATMENT WITH DIFFERENT ANABOLIC AGENTS UNDER STRICTLY STANDARDIZED CONDITIONS. Acta Med Scand. 1965 Feb;177:199-211. PubMed PMID: 14279501.

203: HORTLING H. THE ENDOCRINE TREATMENT OF METASTATIC BREAST CANCER. Geriatrics. 1965 Jan;20:51-60. PubMed PMID: 14249988.

204: Bernard I. [Value of the estro-pgrogestative action of norsteroids in functional uterine hemorrhages]. Gynecol Prat. 1965;16:155-70. French. PubMed PMID: 5878503.

205: MCGARRITY KA. HORMONE THERAPY IN GYNAECOLOGY. Med J Aust. 1964 Nov 28;2:878-83. PubMed PMID: 14218682.

206: WILLIAMS KL. TEMPERATURE MEASUREMENT IN BREAST DISEASE. Ann N Y Acad Sci. 1964 Oct 9;121:272-81. PubMed PMID: 14237519.

207: SEGALOFF A, WEETH JB, CUNINGHAM M, MEYER KK. HORMONAL THERAPY IN CANCER OF THE BREAST. 23. EFFECT OF 7-ALPHA-METHYL-19-NORTESTOSTERONE ACETATE AND TESTOSTERONE PROPIONATE ON CLINICAL COURSE AND HORMONAL EXCRETION. Cancer. 1964 Oct;17:1248-53. PubMed PMID: 14236756.

208: EAKINS D, FULTON T, HADDEN DR. RETICULUM CELL SARCOMA OF THE SMALL BOWEL AND STEATORRHOEA. Gut. 1964 Aug;5:315-23. PubMed PMID: 14209914; PubMed Central PMCID: PMC1413455.

209: HARPMAN JA. ON BLOCK DISSECTION OF THE NECK. Eye Ear Nose Throat Mon. 1964 Jun;43:41-8. PubMed PMID: 14170377.

210: HAMADA M, MIKURIYA S, NAKANO M. [RADIATION THERAPY OF ESOPHAGEAL CANCER AND NUTRITION CONTROL.]. Gan No Rinsho. 1964 May;10:398-402. Japanese. PubMed PMID: 14148074.

211: NISSEN-MEYER R. PROPHYLACTIC ENDOCRINE TREATMENT IN CARCINOMA OF THE BREAST. Clin Radiol. 1964 Apr;15:152-60. PubMed PMID: 14140852.

212: NASIO J. [PALLIATIVE TREATMENT OF INOPERABLE DIGESTIVE CANCER.]. Hisp Med. 1964 Mar;21:165-7. Spanish. PubMed PMID: 14145774.

213: AZARMIE S. LEVEL OF PROTEIN-BOUND AMINOAZO DYES IN RATS GIVEN ANABOLIC HORMONES. Oncology. 1964;18:225-8. PubMed PMID: 14220368.

214: NISSEN-MEYER R. ENDOCRINE TREATMENT OF BREAST CANCER. Acta Unio Int Contra Cancrum. 1964;20:531-4. PubMed PMID: 14151981.

215: HASEGAWA Y, TSUKADA R. [RECENT INFORMATION ON THE THERAPY OF BLOOD DISEASES.]. Chiryo. 1964;46:501-9. Japanese. PubMed PMID: 14126913.

216: RAURAMO L, GROENROOS M. THE USE OF TRENIMON AND DECA-DURABOLIN IN RECURRENT GYNAECOLOGICAL CARCINOMA. Ann Chir Gynaecol Fenn. 1964;53:115-9. PubMed PMID: 14120480.

217: GRANJON A, GIRAUD B. [THE HORMONAL BACKGROUND OF FIBROMAS.]. Rev Prat. 1963 Oct 11;13:3139-43. French. PubMed PMID: 14093322.

218: SICCARDI A, ZANGARA A. [FIRST EXPERIMENTS ON THE ACTION OF NORANDROSTENOLONE PHENYLPROPIONATE (NOR TPP) ON BENZOPYRENE TUMORS IN RATS.]. Arch Maragliano Patol Clin. 1963 Oct;19:571-80. Italian. PubMed PMID: 14093847.

219: ROTH CH. ANABOLIC STEROIDS: REVIEW WITH EMPHASIS ON USE IN OSTEOPOROSIS, SELECTED MALIGNANCIES, AND IN CORTICOSTEROID AND ACTH THERAPY. Am J Orthop. 1963 Oct;5:296-301. PubMed PMID: 14055773.

220: TOTH F. [ON THE CLINICAL SIGNIFICANCE OF SYNTHETIC PROGESTEROIDS AND THEIR POSSIBLE ROLE IN CARCINOGENESIS.]. Z Geburtshilfe Gynakol. 1963 Sep;161:94-102. German. PubMed PMID: 14093621.

221: LANGNICKEL D. [On the treatment of malignant tumors with tris-ethyleneimonobenzoquinone, 19-norandrostenolone decanoate and prednisone.]. Med Welt. 1963 May 4;18:1015-8 passim. German. PubMed PMID: 13928668.

222: MAGGIOLO J. [TREATMENT OF HIRSUTISM OF OVARIAN ORIGIN WITH ANOVULATORY COMPOUNDS.]. An Fac Med Univ Repub Montev Urug. 1963;48:118-20. Spanish. PubMed PMID: 14159997.

223: KALLIOMAEKI JL, SEPPAELAE P. NORANDROSTENOLONE DECANOATE AS A CARDIAC ANABOLIZER STUDIED BY MEANS OF ELECTROCARDIOGRAPHIC CHANGES. Cardiologia. 1963;43:124-8. PubMed PMID: 14060181.

224: VERNE J, ROTH PC. [Preventive action of norandrostenolone phenylpropionate (N.A.P.P.) in experimental tumor induction.]. Bull Assoc Fr Etud Cancer. 1963 Jan-Mar;50:49-52. French. PubMed PMID: 13996833.

225: KLEIBEL F. [The anabolic effect of norsteroids and ethylestrenol in radiotherapy.]. Munch Med Wochenschr. 1962 Dec 21;104:2514-8. German. PubMed PMID: 14033334.

226: DASDIA T, SOLDATI M. [Influence of a testosterone derivative on the growth of spontaneous mammary adenocarcinoma of the mouse in vitro: 4-hydroxy-17alpha-methyl-19-nortestosterone.]. Tumori. 1962 Nov-Dec;48:382-92. Italian. PubMed PMID: 14025187.

227: HORTLING H, MALMIO K, HIISI-BRUMMER L, af BJORKESTEN. Endocrine treatment of metastasizing breast cancer. Acta Med Scand Suppl. 1962;385:1-37. PubMed PMID: 13964039.

228: SZUJEWSKI HA. Nandrolone phenpropionate: a new palliative agent in the management of mammary carcinoma. Am Pract Dig Treat. 1959 Dec;10:2157-9. PubMed PMID: 13836459.